ESCRS - POGAU065 - Real-World Three-Year Outcomes Of The First Miniject Supraciliary Glaucoma Implants In The Uk

Real-World Three-Year Outcomes Of The First Miniject Supraciliary Glaucoma Implants In The Uk

Published 2026 - 44th Congress of the ESCRS

Reference: POGAU065 | Type: Free paper | DOI: 10.82333/mec5-3y08

Authors: Mr Dimitrios Lolos 1 , Mr Aadil Hussain 1 , Dr Maria Pantelidou 1 , Mr Panagiotis Dervenis 2 , Mr Mohammad Ihsan Fazal 3 , Ms Neeru Vallabh 4 , A/Prof. Dan Lindfield 5 , A/Prof. Gerassimos Lascaratos 2 , Mr Chrysostomos Dimitriou* 1

1Colchester Eye Centre,Colchester,United Kingdom, 2King's College Hospital,London,United Kingdom, 3Ipswich Hospital,Ipswich,United Kingdom, 4Liverpool University Hospitals,Liverpool,United Kingdom, 5Farnham Eye Care,Farnham,United Kingdom

Purpose

To evaluate the long-term efficacy and safety of the MINIject supraciliary minimally invasive glaucoma surgery (MIGS) implant in reducing intraocular pressure (IOP) and topical medication burden in patients with medically uncontrolled glaucoma, and to assess outcomes by glaucoma diagnosis, including primary open-angle glaucoma (POAG), primary angle-closure glaucoma (PACG) and normal-tension glaucoma (NTG), disease stage, and surgical approach including standalone and combined procedures.

Setting

Retrospective real-world study conducted at Colchester Eye Centre, a tertiary glaucoma referral centre in the United Kingdom.

Methods

This retrospective study included 31 eyes with various glaucoma types and stages treated with the MINIject supraciliary glaucoma implant either as a standalone procedure or as part of combined procedures with cataract surgery, with follow-up to 36 months. IOP and topical glaucoma medications were recorded at each visit. Paired and independent t-tests were used to assess within-group and subgroup changes. Outcomes were analysed by glaucoma diagnosis, disease stage based on preoperative visual field mean deviation, and surgical approach. Drop-free status and surgical success were documented. Treatment success was defined as ≥20% IOP reduction and/or reduction in topical medications.

Results

Thirty-one eyes were included (POAG 20, PACG 10, NTG 1). Mean IOP decreased from 18.06±5.15 to 13.10±4.52 mmHg at 36 months (−27.5%), and medications from 2.26±1.06 to 1.23±1.12 drops (−45.7%). POAG showed 26.8% IOP and 54% medication reduction, PACG 29.2% IOP and 21% medication reduction. The greatest IOP reduction occurred in advanced glaucoma (−10.5 mmHg). 35.5% of eyes were drop-free at 36 months. Combined procedures (n=24) achieved 29.9% IOP and 51% medication reduction, compared with 17.9% IOP and 31.6% medication reduction in standalone procedures (n=7). Treatment success occurred in 27/31 eyes (87.1%). Four eyes developed hyphema; three resolved spontaneously and one required washout. No additional glaucoma surgery was required.

Conclusions

The MINIject supraciliary glaucoma implant provided sustained reductions in IOP and medication burden over three years in a real-world glaucoma cohort. Approximately one-third of eyes remained drop-free at final follow-up. Outcomes were consistent across glaucoma diagnoses, stages, and surgical approaches including combined procedures, with the greatest pressure reduction observed in advanced glaucoma. The procedure demonstrated a favourable safety profile.